Tapestry Raises Annual Targets but Warns of Soft Holiday Quarter
Tapestry lifted its full-year outlook after a strong quarter driven by Gen Z’s love for Coach handbags but forecast lower holiday earnings amid tariff pressures and cautious spending.
Tapestry lifted its full-year outlook after a strong quarter driven by Gen Z’s love for Coach handbags but forecast lower holiday earnings amid tariff pressures and cautious spending.
Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.
Wolfe Research initiates coverage of Abivax with an Outperform rating and $176 price target, citing strong potential for Crohn’s disease success and upcoming 2026 catalyst.
President Trump announced deals with Eli Lilly and Novo Nordisk to slash GLP-1 obesity drug prices for Medicare/Medicaid and launch TrumpRx.gov. Medicare coverage for these costly treatments begins mid-2026.